Anti-Human CD11a (Efalizumab) - Fc Mutedâ„¢
Anti-Human CD11a (Efalizumab) - Fc Mutedâ„¢ (LT805-GRP)
Products
Description
CD11a and CD18 are the Integrin alpha-L and beta-2 subunits that combine to form LFA-1, a glycoprotein and a member of the Integrin family. The Integrin alpha-L/beta-2 complex is a receptor for ICAM1, ICAM2, ICAM3, ICAM4 and F11R. LFA-1 participates in the immunological synapses between CD8+ T lymphocytes and antigen-presenting cells. Efalizumab binds to the CD11a subunit of LFA-1 and acts as an immunosuppressant by inhibiting lymphocyte activation and cell migration out of blood vessels into tissues. Anti-Human CD11a (Efalizumab) utilizes the same variable regions from the therapeutic antibody Efalizumab making it ideal for research projects.
Specifications
| Manufacturer Cat# | LT805 |
|---|---|
| Concentration | ≥ 5.0 mg/ml |
| Formulation | This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 - 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added. |
| Clone | hu1124 |
| Applications | B, CyTOF®, ELISA, FA, FC, IHC |
| Antigen | CD11a is expressed on all leukocytes. |
| Storage | Functional grade biosimilar antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles. |
| Protein | CD11a |